These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37046323)

  • 21. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?
    Machado MV; Policarpo S; Coutinho J; Carvalhana S; Leitão J; Carvalho A; Silva AP; Velasco F; Medeiros I; Alves AC; Bourbon M; Cortez-Pinto H
    Obes Surg; 2020 Feb; 30(2):560-568. PubMed ID: 31637670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement.
    Koot BG; van der Baan-Slootweg OH; Tamminga-Smeulders CL; Rijcken TH; Korevaar JC; van Aalderen WM; Jansen PL; Benninga MA
    Arch Dis Child; 2011 Jul; 96(7):669-74. PubMed ID: 21518734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers.
    Mazzotti A; Caletti MT; Brodosi L; Di Domizio S; Forchielli ML; Petta S; Bugianesi E; Bianchi G; Marchesini G
    J Hepatol; 2018 Nov; 69(5):1155-1163. PubMed ID: 30290973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective Treatment of Nonalcoholic Fatty Liver Disease Using a Community-Based Weight Management Program.
    Hawa F; Gladshteyn M; Gunaratnam SV; Scheidel C; Corsello PM; Berger SH; Gunaratnam NT
    Cureus; 2021 Jul; 13(7):e16709. PubMed ID: 34466334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnitude of A1C improvement in relation to baseline A1C and amount of weight loss in response to intensive lifestyle intervention in real-world diabetes practice: 13 years of observation.
    Eldib AH; Dhaver S; Al-Badri M; Salah T; Kibaa K; Elenani O; Tomah S; Gardner H; Hamdy O
    J Diabetes; 2023 Jun; 15(6):532-538. PubMed ID: 37194402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of hepatic steatosis index as noninvasive diagnostic tool and liver ultrasound for non-alcoholic steatosis in the adult population.
    Khani V; Momeni Moghaddam A; Hatami B
    Gastroenterol Hepatol Bed Bench; 2022; 15(4):360-365. PubMed ID: 36762218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes.
    Choe EY; Lee YH; Choi YJ; Huh BW; Lee BW; Kim SK; Kang ES; Cha BS; Lee EJ; Huh KB; Younossi ZM
    J Gastroenterol Hepatol; 2018 May; 33(5):1082-1091. PubMed ID: 28990251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study.
    Dai W; Zhang Z; Zhao S
    Front Cardiovasc Med; 2021; 8():680664. PubMed ID: 34490362
    [No Abstract]   [Full Text] [Related]  

  • 31. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study.
    Kouvari M; Polyzos SA; Chrysohoou C; Skoumas J; Pitsavos CS; Panagiotakos DB; Mantzoros CS
    Clin Nutr; 2022 Jun; 41(6):1281-1289. PubMed ID: 35504171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.
    Hamurcu Varol P; Kaya E; Alphan E; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2020 Oct; 32(10):1352-1357. PubMed ID: 32092046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial.
    Unick JL; Beavers D; Jakicic JM; Kitabchi AE; Knowler WC; Wadden TA; Wing RR;
    Diabetes Care; 2011 Oct; 34(10):2152-7. PubMed ID: 21836103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.
    Chen N; Zhou J; Wang K; Li X; Li Z
    BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36792168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
    Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
    J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort.
    Choe HJ; Lee H; Lee D; Kwak SH; Koo BK
    J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):260-269. PubMed ID: 36403577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Impact of Weight Loss on Nonalcoholic Fatty Liver Resolution in a North American Cohort with Obesity.
    Rachakonda V; Wills R; DeLany JP; Kershaw EE; Behari J
    Obesity (Silver Spring); 2017 Aug; 25(8):1360-1368. PubMed ID: 28605159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.